Last reviewed · How we verify

NCT04911582

Does the Bioactive Substance in Coffee, Cafestol, Have Preventive Properties on Type-2-diabetes? (Acute Substudy)

Completed NA Last updated 28 February 2022
What this trial tests

NA trial testing Cafestol 12 mg in Obesity, Abdominal in 15 participants. Completed in 16 September 2021.

Timeline
25 May 2021
Primary endpoint
16 September 2021
16 September 2021

Quick facts

Lead sponsorUniversity of Aarhus
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposetreatment
Enrollment15
Start date25 May 2021
Primary completion16 September 2021
Estimated completion16 September 2021
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

University of Aarhus

Who can join

Adults 18 to 80, any sex, with Obesity, Abdominal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute, double-blinded, randomized, cross-over cafestol intervention study with fifteen participants with a large waist circumference participating in three OGTTs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity, Abdominal

Currently open trials in the same condition.

Other University of Aarhus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04911582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing